Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_assertion type Assertion NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_head.
- NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_assertion description "[TOP2A has aroused particular interest as over-expression of its protein has been shown to correlate, both with amplification of HER2/neu, and with response to anthracycline-based chemotherapeutic agents in breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_provenance.
- NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_assertion evidence source_evidence_literature NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_provenance.
- NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_assertion SIO_000772 20100636 NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_provenance.
- NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_assertion wasDerivedFrom befree-2016 NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_provenance.
- NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_assertion wasGeneratedBy ECO_0000203 NP789293.RAdsBVfhA6XtRROLiQd6oj9P0BvFyECJLDGoQLp8RFS3Q130_provenance.